TriSalus Life Sciences, Inc.
12
1
5
1
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 80/100
33.3%
4 terminated/withdrawn out of 12 trials
20.0%
-66.5% vs industry average
0%
0 trials in Phase 3/4
100%
1 of 1 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (12)
Cryoablation and Arterial Infusion of SD-101 in Combination With Durvalumab and Tremelimumab
Role: collaborator
Pressure-enabled Delivery in Radioembolization (TriNav Study)
Role: collaborator
TriNav Infusion System for the Evaluation of Fidelity Between 99mTc-MAA and Y90-Microspheres Hepatic Distribution for Dosimetry Treatment Planning
Role: collaborator
PREDICTT Clinical Trial: Prospective Evaluation Of Pressure-Enabled Delivery And Alterations In CT-Based Tumor-To-Normal Liver Ratio And Tumor Dose Using The Trinav Infusion System
Role: collaborator
Pembrolizumab +/- SD-101 in Hormone-Naïve Oligometastatic Prostate Cancer With RT and iADT
Role: collaborator
Pressure Enabled Delivery of SD-101 With Checkpoint Blockade for Primary Liver Tumors
Role: lead
Intrahepatic Delivery of SD-101 by Pressure-Enabled Regional Immuno-oncology (PERIO), With Checkpoint Blockade in Adults With Metastatic Uveal Melanoma
Role: lead
Pressure-enabled Retrograde Occlusive Therapy With Embolization for Control of Thyroid Disease (PROTECT Registry): A Multicenter Registry
Role: collaborator
Pressure Enabled Intrapancreatic Delivery of SD-101 With Checkpoint Blockade for Locally Advanced Pancreatic Adenocarcinoma
Role: lead
Lipiodol Deposition Using Endhole vs. Pressure-Modulated Delivery
Role: collaborator
Pain Reduction and Ovarian Perfusion Following Uterine Fibroid Embolization
Role: collaborator
Pressure Enabled Drug Delivery By Pancreatic Retrograde Venous Infusion For Advanced Pancreatic Carcinoma
Role: collaborator
All 12 trials loaded